Global histone modification of H3K27 correlates with the outcomes in patients with metachronous liver metastasis of colorectal cancer

European Journal of Surgical Oncology

Volumn 39, Issue 6, 2013, Pages 655-661

  Tamagawa, H ^a   Oshima, T ^b   Numata, M ^a   Yamamoto, N ^a   Shiozawa, M ^a   Morinaga, S ^a   Nakamura, Y ^a   Yoshihara, M ^a   Sakuma, Y ^a   Kameda, Y ^a   Akaike, M ^a   Yukawa, N ^c   Rino, Y ^c   Masuda, M ^c   Miyagi, Y ^a  

^a KANAGAWA CANCER CENTER   (Japan)

^b YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

EZH2; H3K27; H3K36; Histone modification; Liver metastasis; Prognostic factor

Indexed keywords

HISTONE H3; HISTONE H3 LYSINE 36; UNCLASSIFIED DRUG;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DNA METHYLATION; FOLLOW UP; HISTONE MODIFICATION; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LYMPH NODE METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; COLORECTAL NEOPLASMS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LYSINE; MALE; METHYLATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, SECOND PRIMARY; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TISSUE ARRAY ANALYSIS;

EID: 84877584684     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2013.02.023     Document Type: Article

References (32)

1. B.D. Strahl, and C.D. Allis The language of covalent histone modifications Nature 403 6765 2000 41 45
2. T. Kouzarides Histone methylation in transcriptional control Curr Opin Genet 12 2 2002 198 209
3. M.T. Bedford, and S. Richard Arginine methylation an emerging regulator of protein function Mol Cell 18 3 2005 263 272
4. T. Kouzarides Chromatin modifications and their function Cell 128 4 2007 693 705
5. D.B. Seligson, S. Horvath, and M.A. McBrian Global levels of histone modifications predict prognosis in different cancers Am J Pathol 174 5 2009 1619 1628
6. F. Barlesi, G. Giaccone, and M.I. Gallegos-Ruiz Global histone modifications predict prognosis of resected non small-cell lung cancer J Clin Oncol 25 28 2007 4358 4364
7. A. Van Den Broeck, E. Brambilla, and D. Moro-Sibilot Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer Clin Cancer Res 14 22 2008 7237 7245
8. Y.S. Park, M.Y. Jin, Y.J. Kim, J.H. Yook, B.S. Kim, and S.J. Jang The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma Ann Surg Oncol 15 7 2008 1968 1976
9. Y. Wei, W. Xia, and Z. Zhang Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers Mol Carcinog 47 9 2008 701 706
10. A. Manuyakorn, R. Paulus, and J. Farrell Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704 J Clin Oncol 28 8 2010 1358 1365
11. Y. Toh, M. Yamamoto, and K. Endo Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma Oncol Rep 10 2 2003 333 338
12. S.E. Elsheikh, A.R. Green, and E.A. Rakha Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome Cancer Res 69 9 2009 3802 3809
13. J. Weitz, M. Koch, J. Debus, T. Hohler, P.R. Galle, and M.W. Buchler Colorectal cancer Lancet 365 9454 2005 153 165
14. J. Homsi, and C.R. Garrett Hepatic arterial infusion of chemotherapy for hepatic metastases from colorectal cancer Cancer Control 13 1 2006 42 47
15. H. Tamagawa, T. Oshima, and M. Shiozawa The global histone modification pattern correlates with overall survival in metachronous liver metastasis of colorectal cancer Oncol Rep 27 3 2012 637 642
16. K.S. McCarty Jr., L.S. Miller, E.B. Cox, J. Konrath, and K.S. McCarty Sr. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies Arch Pathol Lab Med 109 8 1985 716 721
17. P.A. Jones, and S.B. Baylin The fundamental role of epigenetic events in cancer Nat Rev Genet 3 6 2002 415 428
18. S.B. Hake, A. Xiao, and C.D. Allis Linking the epigenetic 'language' of covalent histone modifications to cancer Br J Cancer 90 4 2004 761 769
19. R. Kanwal, and S. Gupta Epigenetics and cancer J Appl Physiol 109 2 2010 598 605
20. Y.B. Schwartz, and V. Pirrotta Polycomb silencing mechanisms and the management of genomic programmes Nat Rev Genet 8 1 2007 9 22
21. N.J. Krogan, M. Kim, and A. Tong Methylation of histone H3 by Set2 in Saccharomyces cerevisiae is linked to transcriptional elongation by RNA polymerase II Mol Cell Biol 23 12 2003 4207 4218
22. J.W. Edmunds, L.C. Mahadevan, and A.L. Clayton Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation EMBO J 27 2 2008 406 420
23. S.M. Yoh, J.S. Lucas, and K.A. Jones The Iws1:Spt6:CTD complex controls cotranscriptional mRNA biosynthesis and HYPB/Setd2-mediated histone H3K36 methylation Genes Dev 22 24 2008 3422 3434
24. R.F. Luco, Q. Pan, K. Tominaga, B.J. Blencowe, O.M. Pereira-Smith, and T. Misteli Regulation of alternative splicing by histone modifications Science 327 5968 2010 996 1000
25. J. Ellinger, P. Kahl, and J. von der Gathen Global histone H3K27 methylation levels are different in localized and metastatic prostate cancer Cancer Invest 30 2 2011 92 97
26. S. Rogenhofer, P. Kahl, and C. Mertens Global histone H3 lysine 27 (H3K27) methylation levels and their prognostic relevance in renal cell carcinoma BJU Int 109 3 2012 459 465
27. N. Justin, V. De Marco, R. Aasland, and S.J. Gamblin Reading, writing and editing methylated lysines on histone tails: new insights from recent structural studies Curr Opin Struct Biol 20 6 2010 730 738
28. C.G. Kleer, Q. Cao, and S. Varambally EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells Proc Natl Acad Sci U S A 100 20 2003 11606 11611
29. F.M. Raaphorst, F.J. van Kemenade, and T. Blokzijl Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease Am J Pathol 157 3 2000 709 715
30. Z.K. Qin, J.A. Yang, and Y.L. Ye Expression of Bmi-1 is a prognostic marker in bladder cancer BMC Cancer 9 2009 61
31. T. Sudo, T. Utsunomiya, and K. Mimori Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma Br J Cancer 92 9 2005 1754 1758
32. C.G. Wang, Y.J. Ye, J. Yuan, F.F. Liu, H. Zhang, and S. Wang EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis World J Gastroenterol 16 19 2010 2421 2427